Clinical trials: Skin Cancer Scalp
Actinic Keratoses
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and…
- Trial name
- NCT04085367
- Testing
- MAL 16.8% cream, MAL Vehicle Cream
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive days as field treatment.
- Trial name
- NCT02547363
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- LEO Pharma
Actinic Keratoses
Daylight Photodynamic Therapy for Actinic Keratosis
This is a randomized, single-blind controlled trial with parallel group design to determine whether daylight photodynamic therapy (PDT) affords a reduction in treatment symptoms of pain, burning, and pruritus as measured by 1)…
- Trial name
- NCT03322293
- Testing
- Aminolevulinic Acid Topical 20% Topical Solution, BLU-U blue light phototherapy illuminator
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Actinic Keratosis
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratosis when applied to broad areas on the face and scalp for 1, 2 and 3 hours.
- Trial name
- NCT01475955
- Testing
- Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation
- Where
- 13 sites in United States
- Volunteers
- 235 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Skin Aging, Skin Cancer
Bioclinical Study of Scalp Photoaging of a Population Male Over 65 Years Old.
The aging of skin, especially that of the scalp, is a combination of intrinsic and extrinsic aging factors secondary to the chronic sun exposure.
- Trial name
- BACCHUS (NCT03603587)
- Testing
- biopsy, blood sample, questionnaire on sun exposure
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Breast Neoplasms, Alopecia
Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients
Chemotherapy-induced alopecia (CIA) significantly compromises body image in breast cancer patients, particularly when involving eyebrow and eyelash loss (madarosis).
- Conditions
- Breast Neoplasms, Alopecia, Madarosis, Eyebrow Diseases
- Trial name
- NCT06955702
- Testing
- cryotherapy for chemotherapy-induced madarosis
- Where
- 2 sites in Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Salamanca
Actinic Keratosis
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands
- Trial name
- NCT06319794
- Testing
- Bimiralisib
- Where
- 2 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- TORQUR
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast Cancer
This clinical trial evaluates the benefits of a portable scalp cooling system (PSCS) for improving chemotherapy-induced hair loss in patients with breast cancer that has spread to other places in the body (metastatic) and are…
- Trial name
- NCT05533320
- Testing
- Cold Cap Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Sponsor
- City of Hope Medical Center
Actinic Keratosis
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively.
- Trial name
- NCT02305888
- Testing
- LEO 43204
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- LEO Pharma